Stockscreener 앱 받기
19.45
0.00%
0.00
시간 외 거래:
19.48
0.03
+0.15%
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
DLD Asset Management LP Makes New $250,000 Investment in DBV Technologies S.A. $DBVT - Defense World
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
DBV Technologies to Participate in Upcoming March Investor Conferences - markets.businessinsider.com
Biotech DBV Technologies lines up back-to-back March investor events - Stock Titan
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - ChartMill
DBV Technologies stock surges on new peanut patch trial data - Investing.com
Phase 3 VITESSE data highlighted by DBV Technologies (NASDAQ: DBVT) - Stock Titan
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies Highlights Additional Data from Successful - GlobeNewswire
DBV Technologies (DBVT) Projected to Post Earnings on Thursday - Defense World
European ADRs Were Flat As Biotech Names Took The Lead - Finimize
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
DBV Technologies launches $150M ATM offering - MSN
BioImpact LLC reports 9.99% DBV Technologies (DBVT) stake via shares and warrants - Stock Titan
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - MSN
DBV Technologies to Participate in Biotech Summit - Intellectia AI
DBV Technologies to Present VIASKIN® Data at AAAAI 2026 - Intellectia AI
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies S.A. - Via Ritzau
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit - markets.businessinsider.com
Biotech summit to feature DBV Technologies CEO fireside chat - Stock Titan
DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
European ADRs Slip As Winners And Losers Split By Region - Finimize
European ADRs Inched Higher As GSK And Telefonica Jumped - Finimize
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN) - The Globe and Mail
DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above 50 Day Moving Average – What’s Next? - Defense World
European ADRs Started The Week Higher In US Trading - Finimize
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy? - Defense World
European ADRs Slipped, But Biotech Names Still Stole The Show - Finimize
DBV Technologies Announces €166.7 Million in Gross Proceeds - GlobeNewswire
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025 - GlobeNewswire Inc.
Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday - Benzinga
DBV Technologies stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
1.20%
0.06%
자본화:
|
볼륨(24시간):